Company profile
CordovaCann Corp.
OTC: LVRLF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Toronto, ONCIK 0001168981Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 60
v0.1 · 5/100 weight · pillars only
↑ workforce scale, Piotroski F · ↓ filing timeliness, balance-sheet leverage
Methodology →Revenue TTM
$9.9M
Rev growth YoY (TTM)
-2.2%
Net income (FY)
-$1.8M
Employees
78,574
as of 2026-09-22
Market cap
$4.3M
as of 2026-09-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$1.8M-2.5M CAD2025
Total assets$4.7M6.4M CAD2025
Liabilities$8.5M11.6M CAD2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is CordovaCann Corp.’s financial profile?
CordovaCann Corp. earned -$1.8M in FY2025 net income.
Peers · Healthcare
Kairos Pharma, Ltd.——Liminatus Pharma, Inc. Class A Common Stock——Lakewood-Amedex Biotherapeutics Inc. Common Stock——KMA Holding, Inc.——Adial Pharmaceuticals, Inc.——Cadrenal Therapeutics, Inc. Common Stock——Key facts
CEOThomas Turner Jr.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersToronto, ON
ExchangeOTC: LVRLF
Employees78,574
IPO date2018-03-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.